Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial
Explore this paper's citation graph
Summary
The goal of this study was to evaluate a combination similar to MVP, using carboplatin instead of cisplatin to render it more feasible in an outpatient setting.
- Type
- article
- Published
- 1996-10-15
- Cited by
- 10
- References
- 28
- OpenAlex
- https://openalex.org/W1978586143
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:39823589
Keywords
Medicine, Carboplatin, Vinblastine, Regimen, Lung cancer
References
- Cancer : Principles and Practice of Oncology
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
- Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
- Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.
- A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
- Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
- Cisplatin, etoposide, and ifosfamide in non‐small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm
- Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.
- Dose intensity in lung cancer treatment.
- Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.
- A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma
- Further refinement of carboplatin dosing.
- Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups.
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
- Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
- Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
- The calculation of actual or received dose intensity: a comparison of published methods.
- Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
- Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
Cited by
- Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer.
- A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
- Nitrotriazole AK-2123 Enhances Mitomycin C Activity in Mice Bearing Multidrug-Resistant Tumors
- Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).
- Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
- Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
- Women's health nursing in the context of the National Health Information Infrastructure.
- Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
- Design and Synthesis of Potential Anticancer Agents
- Dosificación de carboplatino: sesgo por sexos y estimaciones inexactas del porcentaje de filtración glomerular
Related papers
- Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy
- In vitro cytotoxicity of cisplatin combined with carboplatin on osteosarcoma cell line OS-732
- Inhibitory Effect of Metal Complexes Cisplatin and Carboplatin of Cervical Cancer Cells
- Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study
- THE COMPARISION OF STUDY BETWEEN CISPLATIN AND CARBOPLATIN IN CHEMOTHERAPY OF CERVICAL CANCER
- Thermochemotherapy with cisplatin or carboplatin in the BT4 rat glioma in vitro and in vivo.
- Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads
- Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay
- New Cisplatin Analogues in Development